DOCSLIB.ORG

Antibiotics and Urinary Tract Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibiotics and Urinary Tract Infections Antibiotics and Urinary Tract Infections Edited by Truls E. Bjerklund Johansen and Kurt G. Naber Printed Edition of the Special Issue Published in Antibiotics www.mdpi.com/journal/antibiotics Truls E. Bjerklund Johansen and Kurt G. Naber (Eds.) Antibiotics and Urinary Tract Infections This book is a reprint of the special issue that appeared in the online open access journal Antibiotics (ISSN 2079-6382) in 2014 (available at: http://www.mdpi.com/journal/antibiotics/special_issues/urinary-tract-infections). Guest Editors Truls E. Bjerklund Johansen Department of Urology, Oslo University Hospital Oslo, Norway Kurt G. Naber Technical University of Munich Munich, Germany Editorial Office MDPI AG Klybeckstrasse 64 Basel, Switzerland Publisher Shu-Kun Lin Production Editor Martyn Rittman 1. Edition 2015 MDPI • Basel • Beijing • Wuhan ISBN 978-3-906980-80-5 © 2015 by the authors; licensee MDPI, Basel, Switzerland. All articles in this volume are Open Access distributed under the Creative Commons Attribution 3.0 license (http://creativecommons.org/licenses/by/3.0/), which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. However, the dissemination and distribution of copies of this book as a whole is restricted to MDPI, Basel, Switzerland. III Table of Contents List of Contributors ................................................................................................................. V Editorial Truls E. Bjerklund Johansen and Kurt G. Naber Urinary Tract Infections Antibiotics 2014, 3(3), 375-377; doi:10.3390/antibiotics3030375 ........................................ VIII http://www.mdpi.com/2079-6382/3/3/375 Chapter 1 Lilian M. Abbo and Thomas M. Hooton Antimicrobial Stewardship and Urinary Tract Infections Antibiotics 2014, 3(2), 174-192; doi:10.3390/antibiotics3020174 ............................................. 1 http://www.mdpi.com/2079-6382/3/2/174 Chapter 2 Daria Nicolosi, Gianna Tempera, Carlo Genovese and Pio M. Furneri Anti-Adhesion Activity of A2-type Proanthocyanidins (a Cranberry Major Component) on Uropathogenic E. coli and P. mirabilis Strains Antibiotics 2014, 3(2), 143-154; doi:10.3390/antibiotics3020143 ........................................... 20 http://www.mdpi.com/2079-6382/3/2/143 Chapter 3 Bernd Wiedemann, Anke Heisig and Peter Heisig Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects Antibiotics 2014, 3(3), 341-352; doi:10.3390/antibiotics3030341 ........................................... 31 http://www.mdpi.com/2079-6382/3/3/341 Chapter 4 Marcelo Hisano, Homero Bruschini, Antonio Carlos Nicodemo and Miguel Srougi Uncomplicated Urinary Tract Infections in Women in a Sao Paulo Quaternary Care Hospital: Bacterial Spectrum and Susceptibility Patterns Antibiotics 2014, 3(1), 98-108; doi:10.3390/antibiotics3010098 ............................................. 43 http://www.mdpi.com/2079-6382/3/1/98 Chapter 5 Winifred Owumi, Niaz Banaei and Linda D. Shortliffe Adult and Pediatric Intra-Institutional Trends of Ciprofloxacin Susceptibility in E. coli Positive Urinary Cultures Antibiotics 2014, 3(2), 163-173; doi:10.3390/antibiotics3020163 ........................................... 53 http://www.mdpi.com/2079-6382/3/2/163 Chapter 6 Ceire Costelloe, O. Martin Williams, Alan A. Montgomery, Colin Dayan and Alastair D. Hay Antibiotic Prescribing in Primary Care and Antimicrobial Resistance in Patients Admitted to Hospital with Urinary Tract Infection: A Controlled Observational Pilot Study Antibiotics 2014, 3(1), 29-38; doi:10.3390/antibiotics3010029 ............................................... 64 http://www.mdpi.com/2079-6382/3/1/29 IV Chapter 7 Franck Bruyère, Joseph-Alain Ruimy, Louis Bernard, Raphael Elfassi, Olivier Boyer, Fabrice Amann and Paul Meria Value of Provoked or Spontaneous Flank Pain in Men with Febrile Urinary Tract Infections Antibiotics 2014, 3(2), 155-162; doi:10.3390/antibiotics3020155 ........................................... 74 http://www.mdpi.com/2079-6382/3/2/155 Chapter 8 Satoshi Takahashi, Hiroshi Kiyota, Shin Ito, Akihiko Iwasawa, Yoshiki Hiyama, Teruhisa Uehara, Koji Ichihara, Jiro Hashimoto, Naoya Masumori, Kenichi Sunaoshi, Koichi Takeda, Nobukazu Suzuki, Takahide Hosobe, Hirokazu Goto, Hidenori Suzuki and Shoichi Onodera Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis Antibiotics 2014, 3(2), 109-120; doi:10.3390/antibiotics3020109 ........................................... 81 http://www.mdpi.com/2079-6382/3/2/109 Chapter 9 Joey Lo, Dirk Lange and Ben H. Chew Ureteral Stents and Foley Catheters-Associated Urinary Tract Infections: The Role of Coatings and Materials in Infection Prevention Antibiotics 2014, 3(1), 87-97; doi:10.3390/antibiotics3010087 ............................................... 93 http://www.mdpi.com/2079-6382/3/1/87 Chapter 10 Walid Elkhatib and Ayman Noreddin In Vitro Antibiofilm Efficacies of Different Antibiotic Combinations with Zinc Sulfate against Pseudomonas aeruginosa Recovered from Hospitalized Patients with Urinary Tract Infection Antibiotics 2014, 3(1), 64-84; doi:10.3390/antibiotics3010064 ............................................. 104 http://www.mdpi.com/2079-6382/3/1/64 Chapter 11 Maria Jose Munoz-Davila Role of Old Antibiotics in the Era of Antibiotic Resistance. Highlighted Nitrofurantoin for the Treatment of Lower Urinary Tract Infections Antibiotics 2014, 3(1), 39-48; doi:10.3390/antibiotics3010039 ............................................. 125 http://www.mdpi.com/2079-6382/3/1/39 Chapter 12 Ekaterina Kulchavenya, Irina Felker and Elena Brizhatyuk International Conference “Urogenital Infections and Tuberculosis” in Novosibirsk, Russia, Has Opened New Perspectives in the Fight against Tuberculosis Antibiotics 2014, 3(2), 121-127; doi:10.3390/antibiotics3020121 ......................................... 135 http://www.mdpi.com/2079-6382/3/2/121 V List of Contributors Fabrice Amann: General Practitioner, 15 rue Jean Baptiste Berlier, Paris 75013, France Niaz Banaei: Departments of Pathology and Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94304, USA Louis Bernard: University Francois Rabelais de Tours, PRES Centre Val de Loire Université, Tours 37000, France; Infectious Disease Department, University Hospital of Tours, Loire Valley 37044, France Olivier Boyer: General Practitioner, 15 rue Jean Baptiste Berlier, Paris 75013, France Elena Brizhatyuk: Novosibirsk Research Institute for Tuberculosis, Novosibirsk 630040, Russia Homero Bruschini: Division of Urology, Hospital das Clinicas-SP, University of Sao Paulo, 255 Doutor Enéas Carvalho de Aguiar Ave., 7th floor, São Paulo 05403-000, Brazil Franck Bruyère: Urology Department, University Hospital of Tours, Loire Valley 37044, France; University Francois Rabelais de Tours, PRES Centre Val de Loire Université, Tours 37000, France Ben H. Chew: Department of Urologic Sciences, University of British Columbia, 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada Ceire Costelloe: Centre for Primary Care and Public health, Blizzard Institute, Queen Mary University of London, London E1 2AB, UK Colin Dayan: Institute of Molecular & Experimental Medicine, Cardiff University School of Medicine, Wales Heart Research Institute, Heath Park, Cardiff CF14 4XN, UK Raphael Elfassi: General Practitioner, 15 rue Jean Baptiste Berlier, Paris 75013, France Walid Elkhatib: Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, African Union Organization St. Abbassia, Cairo 11566, Egypt; Department of Pharmacy Practice, School of Pharmacy, Hampton University, Kittrell Hall Hampton, Virginia 23668, USA Irina Felker: Novosibirsk Research Institute for Tuberculosis, Novosibirsk 630040, Russia Pio M. Furneri: Department of Biomedical Sciences, Section of Microbiology, University of Catania, Via Androne 81, Catania 95124, Italy Carlo Genovese: Department of Biomedical Sciences, Section of Microbiology, University of Catania, Via Androne 81, Catania 95124, Italy Hirokazu Goto: Department of Urology, Fuji City General Hospital, 50 Takashima-Cho, Fuji, Shizuoka 4178567, Japan VI Jiro Hashimoto: Department of Urology, Sapporo Medical University School of Medicine, S. 1, W. 16, Chuo-ku, Sapporo, Hokkaido 0608543, Japan Alastair D. Hay: Centre for Academic Primary Care, NIHR School for Primary Care Research, School of Social and Community Medicine, University of Bristol, Canynge Hall, Bristol BS8 2PS, UK Anke Heisig: Pharmaceutical Biology and Microbiology, Institute of Biochemistry and Molecular Biology, University of Hamburg, Bundesstrasse 45, 20146 Hamburg, Germany Peter Heisig: Pharmaceutical Biology and Microbiology, Institute of Biochemistry and Molecular Biology, University of Hamburg, Bundesstrasse 45, 20146 Hamburg, Germany Marcelo Hisano: Division of Urology, Hospital das Clinicas-SP, University of Sao Paulo, 255 Doutor Enéas Carvalho de Aguiar Ave., 7th floor, São Paulo 05403-000, Brazil Yoshiki Hiyama: Department of Urology, Sapporo Medical University School of Medicine, S. 1, W. 16, Chuo-ku, Sapporo, Hokkaido 0608543, Japan Takahide Hosobe: Hosobe Clinic, 1-1-15, Nezu, Bunkyo-ku, Tokyo 1130031, Japan Koji Ichihara: Department of Urology, Sapporo Medical University School of Medicine, S. 1, W. 16, Chuo-ku, Sapporo, Hokkaido 0608543, Japan Shin Ito: iClinic,
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • List Item Withdrawal Assessment Report for Garenoxacin Mesylate
    European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 18 October 2007 Doc. Ref: EMEA/CHMP/363573/2007 WITHDRAWAL ASSESSMENT REPORT FOR Garenoxacin Mesylate (garenoxacin) EMEA/H/C/747 Day 120 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. This should be read in conjunction with th e "Question and Answer" document on the withdrawal of the application: the Assessment Report may not include all available information on the product if the CHMP assessment of the latest submitted information was still ongoing at the time of the withdrawal of the application. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS I. RECOMMENDATION ........................................................................................................... 3 II. EXECUTIVE SUMMARY...................................................................................................... 3 II.1 Problem statement............................................................................................. .. ..................... 3 II.2 About the product ............................................................................................. .. ..................... 4 II.3 The development programme/Compliance with
    [Show full text]
  • Activity of the Investigational Fluoroquinolone Finafloxacin and Seven Other PD Dr
    Contact information: CORRESPONDING AUTHOR Activity of the Investigational Fluoroquinolone Finafloxacin and Seven Other PD Dr. Reiner Schaumann 49 th ICAAC Institute for Medical Microbiology and Epidemiology of Infectious Diseases San Francisco 2009 Antimicrobial Agents Against 83 Obligately Anaerobic Bacteria. University of Leipzig Liebigstr. 24 1 1 2 1 2 1 D-04103 Leipzig R. SCHAUMANN , G. H. GENZEL , W. STUBBINGS , C. S. STINGU , H. LABISCHINSKI , A. C. RODLOFF Germany E - 1973 Phone +49 341 97 15 200 1Inst. f. Med. Microbiology and Epidemiology of Infectious Diseases, Univ. of Leipzig, Leipzig, Germany; 2MerLion Pharmaceuticals GmbH, Berlin, Germany. Fax +49 341 97 15 209 E-Mail: [email protected] AbstractAbstract MethodsMethods ResultsResults andand DiscussionDiscussion Background: Finafloxacin (FIN) is a novel Bacterial Strains The Figures 2 and 3 show the scatter fluoroquinolone belonging to a 8-cyano subclass 83 obligately anaerobes including reference strains were taken from the histograms of MIC values obtained for FIN culture collection from the Institute for Medical Microbiology and and exhibits enhanced activity at slightly acidic and the seven other antimicrobial agents pH. FIN exhibited superior activity to comparator Epidemiology of Infectious Diseases, University of Leipzig, Germany. The fluoroquinolones in a wide range of rodent strains were collected from clinical specimens at the Institute and from against 83 obligately anaerobic bacteria infection models. With the present study the national and international studies and obtained in part from other included in this study. activity of FIN against 83 recently isolated strains laboratories. The following strains were used: Bacteroides fragils group of obligately anaerobic bacteria including (n=62): B.
    [Show full text]
  • Paper I and II)
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1335 Constraints on up-regulation of drug efflux in the evolution of ciprofloxacin resistance LISA PRASKI ALZRIGAT ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-554-9923-5 UPPSALA urn:nbn:se:uu:diva-320580 2017 Dissertation presented at Uppsala University to be publicly examined in B22, BMC, Husargatan 3, Uppsala, Friday, 9 June 2017 at 09:00 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Faculty examiner: Professor Fernando Baquero (Departamento de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain). Abstract Praski Alzrigat, L. 2017. Constraints on up-regulation of drug efflux in the evolution of ciprofloxacin resistance. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1335. 48 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9923-5. The crucial role of antibiotics in modern medicine, in curing infections and enabling advanced medical procedures, is being threatened by the increasing frequency of resistant bacteria. Better understanding of the forces selecting resistance mutations could help develop strategies to optimize the use of antibiotics and slow the spread of resistance. Resistance to ciprofloxacin, a clinically important antibiotic, almost always involves target mutations in DNA gyrase and Topoisomerase IV. Because ciprofloxacin is a substrate of the AcrAB-TolC efflux pump, mutations causing pump up-regulation are also common. Studying the role of efflux pump-regulatory mutations in the development of ciprofloxacin resistance, we found a strong bias against gene-inactivating mutations in marR and acrR in clinical isolates.
    [Show full text]
  • And Levofloxacin Against Intracellular Staphylococcus Aureus Or Listeria Monocytogenes in J774 Macrophages
    Activity of Garenoxacin (BMS284756) and Levofloxacin Against Intracellular Staphylococcus aureus or Listeria monocytogenes in J774 Macrophages Poster #A1176 P.M. Tulkens C. Seral, P.M. Tulkens and F. Van Bambeke Pharmacologie cellulaire et moléculaire UCL 73.70 av. Mounier 73 Pharmacologie Cellulaire et Moléculaire, Université catholique de Louvain - Brussels - Belgium 1200 Brussels - Belgium [email protected] ABSTRACT INTRODUCTION METHODS (cont’d) RESULTS : pharmacokinetics CONCLUSION Background: ! Eradication of intracellular infections requires the use of antibiotics Activity against intracellular Staphylococcus aureus ATCC 25923: ! Kinetics of Accumulation Both quinolones show a concentration - dependent Quinolones are active against a variety of intracellular able to accumulate in eucaryotic cells at sufficiently high Bacteria were opsonized by human serum during 30 min. Cells were intracellular activity. concentrations.1 Fluoroquinolones (zwitterions) accumulate in cells organisms. Yet, little is known about the relationships infected with an inoculum of 0.5 bacteria/macrophage, and washed and could therefore be used against intracellular bacteria.1,2 garenoxacin 5 µg/ml ! Quinolone activity is lower intracellularly than between intrinsic activity (as determined in broth), cell during 1 h with gentamicin 50 µg/ml after 1 h of phagocytosis at 37°C 6 extracellularly, suggesting a marked defeating effect of accumulation, and intracellular activity. to remove non-phagocytosed and non-firmly adherent bacteria. Cells ! Garenoxacin (BMS-284756; formerly known is T-3811) is a novel the intracellular milieu on activity as compared to broth. des-fluoro (6)-quinolone more active against Gram-postive bacteria were then incubated for up to 24 h with garenoxacin or levofloxacin or Methods: 4 levofloxacin 5 µg/ml and intracellular organisms such as chlamydia.3 with gentamicin at its MIC (0.5 µg/ml; control).4 Mφ were infected with serum-opsonized S.a.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Against Helicobacter Pylori in Vitro and in Vivo Merlion Pharmaceuticals Pte Ltd, Washington DC 2008 05-01 the Capricorn, 1 2 1 1 3 3 1 Science Park 2, A
    Contact information: 48th ICAAC / 46th IDSA, WILL STUBBINGS Antimicrobial Activity of Finafloxacin (FIN) against Helicobacter pylori In Vitro and In Vivo MerLion Pharmaceuticals Pte Ltd, Washington DC 2008 05-01 The Capricorn, 1 2 1 1 3 3 1 Science Park 2, A. BUISSONNIÈRE , H-O. WERLING B. BERGEY , P. LEHOURS , W. STUBBINGS , H. LABISCHINSKI , F. MEGRAUD . Singapore 117528 F1-2038 Phone +65 6829 5600 1INSERM U853, Bordeaux, France, 2Bayer HealthCare AG, Elberfeld, Germany, 3MerLion Pharmaceuticals Pte Ltd, Singapore. [email protected] RevisedRevised abstractabstract MethodsMethods ResultsResults andand DiscussionDiscussion Introduction: FIN is a novel fluoroquinolone (FQ) belonging to a new 8- Minimum inhibitory concentration (MIC) determination Murine model of H. felis infection cyano subclass. FIN exhibits optimal efficacy at slightly acidic pH (5.0 - 6.0), Finafloxacin Levofloxacin Clearance % under which other FQs lose activity. FIN is intended for therapeutic use MICs were determined for FIN and LVX against H. pylori strains (n= 55) that were MIC MIC MIC MIC W 8801, X 7328, 17-8299, H. felis was passaged in mice to achieve a persistent infection that pH 50 90 50 90 X 2752, X 9181, Y 1304 against bacterial infections associated with an acidic environment such as H. obtained from patients gastroscoped in the Southwest of France. MICs were 100 [mg/L] [mg/L] [mg/L] [mg/L] 34-6601 exhibited a similar response to therapy as H. pylori in humans. Triple pylori eradication. The antibacterial activity of FIN, was determined against performed by agar dilution at 3 different pHs: 7.3, 6.3 and 5.3. An inoculum FIN FQ RES and susceptible strains at acidic pH, and against H.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • 200 and 800 Mg) in Healthy Volunteers Receiving a Single Oral Dose
    Pharmacology Chemotherapy 2011;57:97–107 Received: June 9, 2010 DOI: 10.1159/000321028 Accepted after revision: August 30, 2010 Published online: February 28, 2011 Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose a b d Florian M.E. Wagenlehner Christine M. Wagenlehner Birgit Blenk d e e c Holger Blenk Sabine Schubert Axel Dalhoff Kurt G. Naber a Department of Urology, Pediatric Urology and Andrology, Justus Liebig University Giessen, and b c Department of Anesthesia, Evangelisches Krankenhaus, Giessen , Technical University of Munich, Straubing , d e Department of Microbiology, Nürnberg , and University Hospital Schleswig-Holstein, Campus Kiel, Kiel , Germany Key Words Introduction ؒ Finafloxacin ؒ Urine pharmacokinetics ؒ Pharmacodynamics Urinary bactericidal titers Urinary tract infection (UTI) is one of the most com- mon reasons for medical consultation. Uncomplicated UTI are predominantly caused by Escherichia coli, but Abstract also by Proteus mirabilis and occasionally Klebsiella spp., Background: Finafloxacin is a novel 8-cyano-fluoroquino- other Enterobacteriaceae and Staphylococcus saprophyti- lone under investigation for treatment of urinary tract infec- cus ( ! 5% each) [1–3] . Infections with P. mirabilis are sig- tion. Methods: Urinary concentrations and urinary bacteri- nificantly more common in patients over 50 years, where- cidal titers (UBT) of finafloxacin 200- and 800-mg single dos- as infections with S. saprophyticus are more common in es in 6 healthy volunteers were measured up to 48 h. UBT younger patients. Nosocomial UTI, almost always com- were determined for a reference strain and 9 selected clin- plicated, are caused by a wide range of pathogens, most ical uropathogens at the pH of native, acidified (pH 5.5) frequently E.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • The Role of the Immune Response in the Effectiveness of Antibiotic Treatment for Antibiotic Susceptible and Antibiotic Resistant Bacteria
    The role of the immune response in the effectiveness of antibiotic treatment for antibiotic susceptible and antibiotic resistant bacteria. by Olachi Nnediogo Anuforom A thesis submitted to the University of Birmingham for the degree of Doctor of Philosophy. Institute of Microbiology and Infection, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham. May, 2015. University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract The increasing spread of antimicrobial resistant bacteria and the decline in the development of novel antibiotics have incited exploration of other avenues for antimicrobial therapy. One option is the use of antibiotics that enhance beneficial aspects of the host’s defences to infection. This study explores the influence of antibiotics on the innate immune response to bacteria. The aims were to investigate antibiotic effects on bacterial viability, innate immune cells (neutrophils and macrophages) in response to bacteria and interactions between bacteria and the host. Five exemplar antibiotics; ciprofloxacin, tetracycline, ceftriaxone, azithromycin and streptomycin at maximum serum concentration (Cmax) and minimum inhibitory concentrations (MIC) were tested. These five antibiotics were chosen as they are commonly used to treat infections and represent different classes of drug.
    [Show full text]